Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Genitourinary Cancers
What bowel dose constraint do you recommend if you are boosting a pelvic lymph node for prostate cancer?
Do you have a maximum bowel dose constraint?
Answer from: Radiation Oncologist at Community Practice
We generally use 55 Gy to < 5 cc based on Gyne literaturem and try to make sure the high prescribed dose is limited to one wall of bowel loop.
Comments
Radiation Oncologist at Torrance Memorial Medical Center
@Sushil Beriwal, could you share a paper or protoc...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
This is the one I was referring to. It’s a s...
2752
2753
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
60 to 66 Gy at 2 Gy per fraction.
Sign in or Register to read more
6526
6532
Related Questions
Does the presence of Atypical Intraductal Proliferation (AIP) on prostate needle biopsy influence your risk stratification?
How do you counsel patients with high risk prostate cancer treated with RT + long term ADT who want to allow their testosterone level to rise above castration before receiving their next Lupron injection?
How do you assess treatment response after prostate XRT in the setting of low volume metastatic disease?
Would you consider maintenance immunotherapy after cisplatin-gemcitabine chemotherapy and chemoRT for stage 3 bladder cancer in a patient declining cystectomy or who is a poor surgical candidate?
Would you offer pelvic nodal RT due to failure after previous pelvic node SBRT in oligorecurrent prostate cancer?
Do you advise Kegels/pelvic floor physical therapy to minimize urinary incontinence when irradiating the prostatic fossa?
After the results of RTOG 0232, would you be comfortable treating unfavorable intermediate risk prostate cancer with brachytherapy monotherapy?
Do you use oncotype DX to change the risk group for prostate cancer from favorable to unfavorable intermediate risk?
How would you treat high risk prostate cancer in a patient with autonomic bladder dysfunction?
Are there any patient characteristics that make you change fractionation when treating per STAMPEDE?
@Sushil Beriwal, could you share a paper or protoc...
This is the one I was referring to. It’s a s...